- AstraZeneca plc AZN is reportedly creating a separate division for vaccines and antibody therapies, primarily to focus on its COVID-19 shot and coronavirus treatments after a shaky start during the pandemic.
- Related Link: AstraZeneca Looking At Potential Options for COVID-19 Vaccine Business: Reuters.
- The new division will combine R&D, manufacturing, and commercial and medical teams.
- Iskra Reić, currently executive vice-president for the Europe and Canada region, will lead the new unit.
- "The team will be dedicated to our COVID-19 vaccine, our long-acting antibody combination, and our developmental vaccine addressing multiple variants of concern, as well as to our existing portfolio for a respiratory viral disease," AstraZeneca's representative said.
- The move comes after the COVID-19 vaccine (Vaxzevria) witnessed several setbacks, including manufacturing problems, concerns over a very rare blood clotting side effect, and disputes over data underpinning its efficacy.
- AstraZeneca will report its third-quarter earnings on Friday, November 12, and has delivered more than 1.9 billion doses of its far cheaper shot.
- Price Action: AZN shares are up 0.77% at $63.18 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
